John Winterton, MD
Cardiovascular Disease · Lake Charles, LANPI 1114018819
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Novartis accounts for 60.9% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2019 at $9,803 and has fallen 78.2% since, to $2,141 in 2025.
Across 299 payments — averaging $50.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$9K
- AOP Health US, LLC$925
- Amgen$506
- Merck$478
- Pfizer$466
- Johnson & Johnson$366
- plus $3K from 33 others
What the payments were for
- Speaking & faculty fees$7,34049%
- Travel & lodging$1,1398%
- Food & beverage$6,49143%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 35 | $9,127 |
| AOP Health US, LLC | 1 | $925 |
| Amgen | 28 | $506 |
| Merck | 28 | $478 |
| Pfizer | 33 | $466 |
| Johnson & Johnson | 24 | $366 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $345 |
| Boehringer Ingelheim | 13 | $310 |
| E.r. Squibb & Sons, L.L.C. | 18 | $283 |
| Medtronic(2 entities) | 6 | $226 |
| Kestra Medical Technology Services, Inc. | 3 | $210 |
| Inari Medical, Inc. | 10 | $198 |
| Abiomed | 7 | $192 |
| Abbott | 4 | $151 |
| Bayer | 7 | $122 |
| Itamar Medical Inc | 3 | $113 |
| Esperion Therapeutics, Inc. | 8 | $110 |
| Shockwave Medical, Inc | 1 | $100 |
| Cvrx, Inc. | 3 | $71 |
| Stryker | 4 | $67 |
| United Therapeutics Corporation | 5 | $63 |
| Boston Scientific | 3 | $60 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Inspire Medical Systems, Inc. | 1 | $53 |
| Philips North America LLC | 3 | $47 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Recor Medical Inc | 2 | $42 |
| Novo Nordisk | 2 | $36 |
| Gilead | 2 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| AstraZeneca | 2 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Chiesi USA, Inc. | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$8,479
- Rapiblyk$1,850
- Assure WCD$159
- Repatha$125
- JARDIANCE$125
- COBALT DR MRI SURESCAN$101
- Vascular Lithotripsy$100
How this compares
$14,998 in reported general payments places this provider in the 85th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 223 | $195,859 |
| EntrestoSacubitril/Valsartan | 55 | $51,128 |
| JardianceEmpagliflozin | 15 | $16,506 |
| Praluent PenAlirocumab | 12 | $6,724 |
| XareltoRivaroxaban | 12 | $6,690 |
| Repatha SyringeEvolocumab | 12 | $6,419 |
| Nebivolol Hcl | 94 | $4,879 |
| Ranolazine ErRanolazine | 20 | $1,375 |
| Labetalol Hcl | 72 | $1,328 |
| Ezetimibe | 74 | $1,310 |
| Irbesartan | 123 | $1,215 |
| Nifedipine ErNifedipine | 80 | $933 |
| Rosuvastatin Calcium | 148 | $840 |
| Metoprolol Succinate | 108 | $732 |
| Losartan Potassium | 88 | $663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $466 | $195,859223 claims |
| NovartisEntresto | $9,127 | $51,12855 claims |
| Boehringer IngelheimJardiance | $310 | $16,50615 claims |
| Johnson & JohnsonXarelto | $366 | $6,69012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Lake Charles
- Corey FosterLake Charles$158K
- Richard GilmoreLake Charles$45K
- Ahmad AwanLake Charles$13K
- Michael TurnerLake Charles$11K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- George KaramBaton Rouge$110K
- Harry HawthorneAlexandria$89K
- Mazen IqbalMonroe$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.